Targeting immunometabolic pathways for combination therapy in Alzheimer's disease.

ABSTRACT: The recent success of disease-modifying anti-amyloid monoclonal antibodies in slowing Alzheimer's disease (AD) symptoms has been an exciting step forward for the field. Despite successfully clearing amyloid from the brain, however, only modest symptomatic improvement has been demonstrated, and treatment-related side effects such as amyloid-related imaging abnormalities (ARIA) limit use for some. These limitations suggest that fully efficacious AD treatment may require combination therapy regimens, as are used in other complex disorders such as cancer and HIV. One reasonable strategy may be to use agents that address the biological changes that predict future amyloid accumulation, or accompany amyloid accumulation in preclinical disease states. Immunometabolic pathways, including the insuli

SUBMITTER: Erichsen J 

PROVIDER: S-EPMC10541802 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature